Original articleCromolyn sodium in the management of systemic mastocytosis☆
References (7)
- et al.
Comparison of the therapeutic efficacy of cromolyn sodium with that of combined chlorpheniramine maleate and cimetidine in systemic mastocytosis
Am J Med
(1985) - et al.
Oral disodium cromoglycate in the treatment of systemic mastocytosis
N Engl J Med
(1979) - et al.
Urticaria pigmentosa: clinical picture and responses to oral sodium cromoglycate
Br J Dermatol
(1981)
There are more references available in the full text version of this article.
Cited by (152)
Diagnostic and therapeutic management of mast cells activation syndromes
2022, Revue Francaise d'AllergologieMast Cell Diseases in Practice and Research: Issues and Perspectives Raised by Patients and Their Recommendations to the Scientific Community and Beyond
2022, Journal of Allergy and Clinical Immunology: In PracticePersonalized Management Strategies in Mast Cell Disorders: ECNM-AIM User's Guide for Daily Clinical Practice
2022, Journal of Allergy and Clinical Immunology: In PracticeUpdate on diagnostic approaches and therapeutic strategies in systemic mastocytosis
2022, Best Practice and Research: Clinical HaematologyFood Allergies and Intolerances: A Clinical Approach to the Diagnosis and Management of Adverse Reactions to Food
2021, Clinical Gastroenterology and HepatologyTreatment of systemic mastocytosis: Novel and emerging therapies
2021, Annals of Allergy, Asthma and ImmunologyCitation Excerpt :For these reasons, treatment with antihistamines is the mainstay of therapy for all forms of mastocytosis. Data to support the use of montelukast12 and oral cromolyn13 are also available. Montelukast is a cysteinyl leukotriene receptor antagonist.
- ☆
Supported by National Institutes of Health Grants AI-22531, AI-23401, AR-35907, and a grant from the Hyde and Watson Foundation.
Copyright © 1990 Published by Mosby, Inc.